WO2016100652A2 - Process for the preparation of a diarylthiohydantoin compound - Google Patents

Process for the preparation of a diarylthiohydantoin compound Download PDF

Info

Publication number
WO2016100652A2
WO2016100652A2 PCT/US2015/066356 US2015066356W WO2016100652A2 WO 2016100652 A2 WO2016100652 A2 WO 2016100652A2 US 2015066356 W US2015066356 W US 2015066356W WO 2016100652 A2 WO2016100652 A2 WO 2016100652A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
temperature
organic solvent
group
Prior art date
Application number
PCT/US2015/066356
Other languages
French (fr)
Other versions
WO2016100652A3 (en
Inventor
Cyril Ben HAIM
Andras Horvath
Johan Erwin Edmond Weerts
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2970937A priority Critical patent/CA2970937A1/en
Priority to EP18170050.1A priority patent/EP3372586A1/en
Priority to JP2017532725A priority patent/JP6681902B2/en
Priority to BR112017013113-7A priority patent/BR112017013113B1/en
Priority to EP18169895.2A priority patent/EP3372585B1/en
Priority to EP18169756.6A priority patent/EP3372584B9/en
Priority to PL18169756T priority patent/PL3372584T3/en
Priority to MDE20170208T priority patent/MD3233803T2/en
Priority to ES15823875T priority patent/ES2718539T3/en
Priority to AU2015364537A priority patent/AU2015364537B2/en
Priority to IL252843A priority patent/IL252843B1/en
Priority to MEP-2019-86A priority patent/ME03420B/en
Priority to EP15823875.8A priority patent/EP3233803B1/en
Priority to MX2017008179A priority patent/MX2017008179A/en
Priority to PL15823875T priority patent/PL3233803T3/en
Priority to UAA201707588A priority patent/UA123201C2/en
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Priority to DK15823875.8T priority patent/DK3233803T3/en
Priority to KR1020177019551A priority patent/KR102586059B1/en
Priority to EA201791390A priority patent/EA201791390A1/en
Priority to NZ732766A priority patent/NZ732766A/en
Priority to MA41200A priority patent/MA41200B1/en
Priority to SI201530599T priority patent/SI3233803T1/en
Priority to CN201580069602.5A priority patent/CN107108507B/en
Priority to SG11201704969QA priority patent/SG11201704969QA/en
Priority to RS20190350A priority patent/RS58454B1/en
Priority to CN202410667649.2A priority patent/CN118638097A/en
Priority to LTEP15823875.8T priority patent/LT3233803T/en
Publication of WO2016100652A2 publication Critical patent/WO2016100652A2/en
Publication of WO2016100652A3 publication Critical patent/WO2016100652A3/en
Priority to PH12017501152A priority patent/PH12017501152A1/en
Priority to ZA2017/04877A priority patent/ZA201704877B/en
Priority to HRP20190540TT priority patent/HRP20190540T1/en
Priority to CY20191100400T priority patent/CY1121684T1/en
Priority to CY20201101031T priority patent/CY1123611T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention is directed to the preparation of compound (X) and intermediates in its synthesis. More specifically, the present invention is directed to processes for the preparation of compound (X), disclosed in United States Patent No. 8,445,507, issued on May 21, 2013, which is hereby incorporated by reference in its entirety.
  • Compound (X) of the present invention is currently being investigated for the treatment of prostate cancer.
  • the present invention describes a process and intermediates for the preparation of such compound.
  • the present invention is directed to a process for the preparation of compound (X)
  • compound (XVII), wherein W is methylamino is converted to compound (X), as shown in scheme (2e), by
  • alkyl refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., Cj.g) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyi-containmg substituent.
  • substituent groups with multiple alkyl groups such as, (Ci-ealkyljiamino-, the C h alky! groups of the dialkyiamino may be the same or different.
  • alkoxy refers to an -Q-aikyl group, wherein the term “alkyl” is as defined above.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • aryl refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.
  • halogen refers to fluorine, chlorine, bromine and iodine atoms.
  • room temperature or “ambient temperature”, as used herein refers to a temperature in the range of from about 18 °C to about 22 °C.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl” and "aryl.”
  • Designated numbers of carbon atoms e.g., Ci-Ce refer independently to the number of carbon atoms in an alkyl moiety, an aryl moiety, or in the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • the designated number of carbon atoms includes all of the independent members included within a given range specified.
  • C j alkyl would include methyl, ethyl, propyl, butyl, pentyi and hexyl individually as well as sub-combinations thereof (e.g., C1.2, C1.3, CH C1.5. C 2 -6, C3.6, C4-6, C5.6, €2-5 , etc.).
  • a "Ci-Ce alkylcarbonyl" substituent refers to a group of the formula:
  • a compound of formula ( ⁇ -c) possesses group P, a conventional ammo protecting group such as a carbamate (-NHC0 2 R) wherein R is C 1-8 alkyl, phenyl, aryl(C 1-8 )alkyl, or the like.
  • a compound of formula ( ⁇ -c) may be reacted with compound (IV) under amide-bond formation conditions in the presence of an amide coupling reagent selected from 1 ,1-carbonyldi imidazole, T3P, EDCI, DMTMM, EEDQ, or the like; in the presence of a catalyst that may be (1) an amidine such as DBU or DBN, (2) a tertiary amine such as DABCO, triethylamine, or DIPEA, (3) a guanidine such as TBD, TMG, or MTBD, or (4) a base such as NaH, OtBu, and LiHMDS, or the like; in an aprotic solvent such as toluene, MeTHF, THE, iPrOAc, or DCM; or a protic solvent such as IP A or the like; at a temperature in the range of from about 0 °C to about 50 °C; to yield the corresponding compound of formula (XII-c).
  • the amide coupling agent is 1,1-carbonyldiimidazole and the catalyst is DBU.
  • compound (IV) may be treated first with either phosgene or a phosgene analog selected from tnphosgene (bis(tnchloromethyl) carbonate), diphosgene (trichloromethyl chloroformate), or the like; in the presence of a tertiary amine base selected from triethylamme, ethyl diisopropylamine, or DABCQ; in an aprotic solvent selected from DCM, toluene, THF, or MeTHF; at a temperature in the range of from about -20 °C to about 50 °C; to form 5-isocyanato-3-(trifluoromethyl)picolinonitrile (IVa) as an intermediate.
  • phosgene or a phosgene analog selected from tnphosgene (bis(tnchloromethyl) carbonate), diphosgene (trichloromethyl chloroformate), or the like
  • a tertiary amine base selected from
  • a non-nucleophilic base that is (1) an amidine such as DBU or DBN, (2) a tertiary amine such as DABCO or triethylamine, or (3) a guanidine such as TBD, TMG, or MTBD; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound of formula (XII-c).
  • the amino group of a compound of formula (XII-c) may be deprotected using conventional methods such as under acidic conditions in an organic solvent such as isopropanol, toluene, MeTHF, THF, iPrOAc, DCM, IPA, water, or the like; at a temperature greater than ambient temperature; to yield the corresponding compound (XIII).
  • organic solvent such as isopropanol, toluene, MeTHF, THF, iPrOAc, DCM, IPA, water, or the like
  • Compound (XIII) may be reacted with a compound of formula (2c- 1) wherein X is chloro, bromo, or iodo and W is C 1-8 alkoxy or methylamino; in the presence of either (1) a Cu(0) source such as copper powder or copper sponge, or (2) a copper salt selected from cuprous chloride, cuprous iodide, cuprous bromide, cuprous acetate, or cupric bromide; in the presence of an inorganic base such as potassium acetate, potassium carbonate, cesium carbonate, CsF, sodium pivalate, or the like; in an organic solvent such as DMF, DMA, DMSO, acetonitrile, propionitrile, butyronitrile, or an alcoholic solvent such as amyl alcohol; with or without the addition of a Cu (I) salt selected from cuprous chloride, cuprous iodide, cuprous bromide, or cuprous acetate; and optionally in the presence of a ligand such as 2-
  • the copper salt is cuprous bromide and the ligand is TMEDA.
  • the Cu(0) source is copper powder.
  • the Cu(0) source is copper sponge.
  • the organic solvent is DMA.
  • the organic solvent is DMSO.
  • reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a copper salt such as cuprous bromide with the ligand TMEDA; in the presence of the inorganic base potassium acetate; in an organic solvent such as DMA; at a temperature range of from about 80 °C to about 140 °C.
  • reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a Cu(0) source such as copper powder or copper sponge; in the presence of an inorganic base such as potassium acetate or sodium pivaiate; in DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
  • the reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a Cu (0) source such as copper powder or copper sponge; in the presence of an inorganic base such as potassium acetate; with the addition of a copper (I) salt selected from cuprous chloride, cuprous iodide, cuprous bromide, or cuprous acetate; in an organic solvent such as DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
  • a Cu (0) source such as copper powder or copper sponge
  • an inorganic base such as potassium acetate
  • a copper (I) salt selected from cuprous chloride, cuprous iodide, cuprous bromide, or cuprous acetate
  • an organic solvent such as DMSO
  • the present invention further includes processes for the conversion of a compound of formula (2c-2) to compound (X), described in detail as follows.
  • Compound (XVII), wherein W is methylamino may be reacted with a thiocarboiiyl source selected from ⁇ , ⁇ '-di(pyridin-2-yl)carbonothioate, l,r-thiocarbonylbis(pyridin- 2(lH)-one), di( lH-imidazol-l -yl)methanethione, thiophosgene, an aryl thionochloroformate (wherein aryl is phenyl, naphthyl, or tolyl), or thiocarbonyl bis(benzotriazole); in the presence of an activating agent selected from DMAP, NaH, or NaOH; in an organic solvent selected from DMA, DMF, toluene, DMSO, ACN, THF, DCM, EtOAc, acetone, MEK, or dioxane; optionally in the presence of an organic base selected from triethylamme or
  • the thiocarbonyl source is l, -thiocarbonylbis(pyridin-2(lH)- one).
  • the activating agent is DMAP
  • the organic solvent is DMA.
  • the thiocarbonyl source is phenyl thionochloroformate; the activating agent is DMAP; the organic base is selected from triethylamine or DIPEA; the organic solvent is DMA; and at a temperature in the range of from about -20 °C to about 80 °C.
  • phenyl thionochloroformate may react with DMAP to form an isoiatable quaternary salt, compound (SI), shown below.
  • the present invention is further directed to a process comprising, consists of, or consists essentially of reacting compound (XVII) with compound SI; in the presence of an organic base selected from triethylamine or DIPEA; in the organic solvent DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
  • a compound of formula (2c ⁇ 2B), wherein W is Ci..gaikoxy, may be reacted with a thiocarbonyl source selected from ⁇ , ⁇ '-di(pyridin-2-yl)carbonothioate, 1 , I '
  • an activating agent selected from DMAP, NaH, or NaOH
  • organic solvent selected from dimethylacetamide, DMF, toluene, DMSO, T
  • W of a compound of formula (2c-2B) is methoxy, designated as compound (XV).
  • the present invention is further directed to a process including reacting compound (2c- 2B) with compound SI; in the presence of an organic base selected from triethylamine or DIPEA; in the organic solvent DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
  • the compound of formula (2e) may be treated with methylamine; in an organic solvent selected from THF, DMF, DMA, ethanol, or an aqueous mixture thereof; at about ambient temperature; to yield the corresponding compound (X).
  • the organic solvent is ethanol.
  • reaction conditions selected from Fl to Fl I, shown in Table 1 may be used for the conversion of Cpd (2c-2) to either compound (X) or a compound of formula (2e), wherein W is methylamino or C 1-8 alkoxy, respectively.
  • DMAPA thionochloroformate
  • Method A A reactor was charged with 1 g of compound (XV), 1.1 g of ⁇ , ⁇ - thiocarbonylbis(pyridin-2(lH)-one), 0.56 g of DMAP and 6.2 mL of DMA. The mixture was stirred and heated to 60 C 'C for 20 h. At that time, 6 mL of EtOH was added, followed by 6 mL of water. The reaction was then cooled to 0 °C. Compound (IX) was isolated by filtration in 70 % yield. 1 H NMR (300 MHz, DMSO) ⁇ 9.23 ( s, j 1.9Hz. 1H), 8.77 ( s, j 2. I I I/.
  • Method B A reactor was charged with 0.5 g of compound (XV), 0,35 g (2.5 eq) of
  • Step B Preparation of Compound (X) from Compound (XVII).
  • Method A A reactor was charged with 48 g of Compound ( XYH ), 52.8 g of 1, 1'- thiocarbonylbis(pyridin-2(lH)-one), 13.5 g of 4-dimethylaminopyridine and 144 mL of DMA. The mixture was stirred and heat to 90 °C for 2 h. The reaction was then cooled to 60 °C. A volume of 37 mL of HCl (6 M in isopropanoi) was added, followed by 144 mL of isopropanol and 216 raL of water. Compound (X) was isolated by filtration in 80 % yield.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.

Description

PROCESS FOR THE PREPARATION OF A DIARYLTfflOHYDANTOIN
COMPOUND
CROSS-REFERENCE TO RELATED APPLICATIONS
This Application claims priority to United States Provisional Patent Application No. 62/094,436, filed December 19, 2014, which is hereby incorporated by reference in its entirety. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
FIELD OF THE INVENTION
The present invention is directed to the preparation of compound (X) and intermediates in its synthesis. More specifically, the present invention is directed to processes for the preparation of compound (X), disclosed in United States Patent No. 8,445,507, issued on May 21, 2013, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Compound (X) of the present invention is currently being investigated for the treatment of prostate cancer. The present invention describes a process and intermediates for the preparation of such compound.
SUMMARY OF THE INVENTION
The present invention is directed to a process for the preparation of compound (X)
I
Figure imgf000003_0001
mprising, consisting of and/ or consisting essentially of
Figure imgf000003_0002
(i) reacting a compound of formula (ΧΓ-c), wherein P is a suitable ammo protecting group, with compound (IV) under amide-bond formation conditions; in the presence of an amide coupling reagent; and in the presence of a catalyst; in an organic solvent; at a temperature in the range of from about 0 °C to about 50 °C; to yield the corresponding compound of formula (ΧΠ-c); or,
Figure imgf000003_0003
5-isocyanato-3-(trifluoromethyl)picolinonitrile (2a- 1 )
(li) reacting compound (IV) with phosgene or a phosgene analog; in the presence of an organic base; in an aprotic solvent; then treating a resulting isocyanate intermediate (IVa), optionally without isolation, with a compound of formula (XI-c); in the presence of a non-nucleophilic base; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound of formula (XII-c);
Figure imgf000004_0001
reacting a compound of formula (XII-c) under suitable amino deprotection conditions; in an organic solvent; at a temperature greater than ambient temperature; to yield the corresponding compound (XIII);
Figure imgf000004_0002
reacting compound (XIII) with a compound of formula (2c- 1) wherein X is chloro, bromo, or iodo and W is Cj.galkoxy or methylamino; in the presence of a Cu(0) source or ι copper salt; in the presence of an inorganic base; in an organic solvent; optionally in the presence of a ligand; optionally in the presence of a suitable reducing agent; at a temperature in the range of from about room temperature to about 140 °C; to yield the corresponding compound of formula (2c~2) wherein W is C1-8alk:oxy or methylamino;
Figure imgf000004_0003
converting a compound of formula (2c-2) to compound (X), discussed in further detail below. In one embodiment, compound (XVII), wherein W is methylamino, is converted to compound (X), as shown in scheme (2e), by
Figure imgf000005_0001
reacting compound (XVII) with a thiocarbonyl source; in the presence of an activating agent; in an organic solvent; optionally in the presence of an organic base; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound (X).
In another embodiment, a compound of formula (2c-2B), wherein W is Ci.galkoxy, is converted to a compound of formula (2e), as shown in scheme (2f), by
Figure imgf000005_0002
reacting a compound of formula (2c-2B) with a thiocarbonyl source; in the presence of an activating agent; in an organic solvent; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound of formula (2e); then
Figure imgf000005_0003
treating a compound of formula (2e) with methylamine; in an organic solvent; at about ambient temperature; to yield the corresponding compound (X). DETAILED DESCRIPTION OF THE INVENTION The term "alkyl" whether used alone or as part of a substituent group, refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., Cj.g) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyi-containmg substituent. In substituent groups with multiple alkyl groups such as, (Ci-ealkyljiamino-, the Chalky! groups of the dialkyiamino may be the same or different.
The term "alkoxy" refers to an -Q-aikyl group, wherein the term "alkyl" is as defined above.
The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
The term "aryl" refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.
The term "halogen", "halide", or "halo" refers to fluorine, chlorine, bromine and iodine atoms.
The term "carboxy" refers to the group -C(=0)OH.
The term "formyl" refers to the group -C(=0)H.
The term "oxo" or "oxido" refers to the group (==0).
The term "thiono" refers to the group (:=S).
The term "room temperature" or "ambient temperature", as used herein refers to a temperature in the range of from about 18 °C to about 22 °C.
Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., Ci-Ce) refer independently to the number of carbon atoms in an alkyl moiety, an aryl moiety, or in the alkyl portion of a larger substituent in which alkyl appears as its prefix root. For alkyl and alkoxy substituents, the designated number of carbon atoms includes all of the independent members included within a given range specified. For example C j alkyl would include methyl, ethyl, propyl, butyl, pentyi and hexyl individually as well as sub-combinations thereof (e.g., C1.2, C1.3, CH C1.5. C2-6, C3.6, C4-6, C5.6,€2-5, etc.).
In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. Thus, for example, a "Ci-Ce alkylcarbonyl" substituent refers to a group of the formula:
O
H
·■(' CrC6 alkyl
Abbreviations used in the instant specification, particularly the schemes and examples, are as follows:
Abbreviations
ACN acetonitnle
aq aqueous
Boc tert-butoxycarbonyl
CDI 1 , 1 ' -carbonyidirmidazoie
DABCO 1 ,4-diazabicyclo[2.2.2]octane
DBN l,5-diazabicyclo(4.3.0)non-5-ene
DBU 1 ,8-diazabicyclo[5.4.0]undec-7-ene
DCM dichloromethane
DIEA or DIPEA diisopropylethylamine
DMA dim ethy lacetami de
DMAPA dimethylaminopropylamine or N^N^dimethylpropane-l^- diamine
DMAP 4 -(dimethylamino)pyridine
DMF dimethylformamide
DMSO dimethyl sulfoxide
DMTMM 4-(4,6-dimethox -l,3,5-triazin-2-yl)-4- methylmorpholinium chloride Abbreviations
1 , 1 '-bis(diphenylphosphino)ferrocine l-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EEDQ 2-ethoxy- 1 -ethoxycarbonyl- 1 ,2-dihydroquinoline h hour(s)
HC1 hydrochloric acid
HPLC high performance liquid chromatography
iPrOAc isopropyiacetate
LiHMDS lithi urn h examethy idi si lazi de
Me methyl
MeCN acetonitrile
MEK methyl ethyl ketone
MeOH methyl alcohol
mg milligram
MTBD 9-methyl-2,3,4,6,7,8-hexahydropyrimido[l ,2- ]pyrimidine
NMP N-methyl-2-pyrrolidone
PdCl2(dppf)'CH2Cl2 1 , 1 '-bis(diphenylphosphino)ferrocene-palladium(n)dichlorii dichloromethane complex)
P(o~tol)3 tri(o-tolyl)phosphine
It room temperature
T3P propylphosphonic anhydride
TBD l ,5,7-triazabicyclo[4.4.0]dec-5-ene
TCDI 1 ,Γ-thiocarbonyl-di-imidazole
THF tetrahydrofuran
TMEDA N,N,Ar'',N'-tetramethylethylenediamine
TMG tetramethylguanidine
2-MeTHF 2-methyl tetrahydrofuran General Schemes
The overall scheme for the invention is illustrated in Scheme A, below.
Selieme A
Figure imgf000009_0001
in Scheme A, a compound of formula (ΧΓ-c) possesses group P, a conventional ammo protecting group such as a carbamate (-NHC02R) wherein R is C1-8alkyl, phenyl, aryl(C1-8)alkyl, or the like. A compound of formula (ΧΓ-c) may be reacted with compound (IV) under amide-bond formation conditions in the presence of an amide coupling reagent selected from 1 ,1-carbonyldi imidazole, T3P, EDCI, DMTMM, EEDQ, or the like; in the presence of a catalyst that may be (1) an amidine such as DBU or DBN, (2) a tertiary amine such as DABCO, triethylamine, or DIPEA, (3) a guanidine such as TBD, TMG, or MTBD, or (4) a base such as NaH, OtBu, and LiHMDS, or the like; in an aprotic solvent such as toluene, MeTHF, THE, iPrOAc, or DCM; or a protic solvent such as IP A or the like; at a temperature in the range of from about 0 °C to about 50 °C; to yield the corresponding compound of formula (XII-c). One of ordinary skill in the art will
recognize that some reagents and bases may not be compatible with every solvent disclosed herein, but reagent and base compatibility may be readily identified using knowledge either already known or available in the scientific literature.
In one embodiment, the amide coupling agent is 1,1-carbonyldiimidazole and the catalyst is DBU.
Alternatively, compound (IV) may be treated first with either phosgene or a phosgene analog selected from tnphosgene (bis(tnchloromethyl) carbonate), diphosgene (trichloromethyl chloroformate), or the like; in the presence of a tertiary amine base selected from triethylamme, ethyl diisopropylamine, or DABCQ; in an aprotic solvent selected from DCM, toluene, THF, or MeTHF; at a temperature in the range of from about -20 °C to about 50 °C; to form 5-isocyanato-3-(trifluoromethyl)picolinonitrile (IVa) as an intermediate. Reaction of intermediate (IVa) with compound (XI-c); in the presence of a non-nucleophilic base that is (1) an amidine such as DBU or DBN, (2) a tertiary amine such as DABCO or triethylamine, or (3) a guanidine such as TBD, TMG, or MTBD; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound of formula (XII-c).
The amino group of a compound of formula (XII-c) may be deprotected using conventional methods such as under acidic conditions in an organic solvent such as isopropanol, toluene, MeTHF, THF, iPrOAc, DCM, IPA, water, or the like; at a temperature greater than ambient temperature; to yield the corresponding compound (XIII).
Compound (XIII) may be reacted with a compound of formula (2c- 1) wherein X is chloro, bromo, or iodo and W is C1-8alkoxy or methylamino; in the presence of either (1) a Cu(0) source such as copper powder or copper sponge, or (2) a copper salt selected from cuprous chloride, cuprous iodide, cuprous bromide, cuprous acetate, or cupric bromide; in the presence of an inorganic base such as potassium acetate, potassium carbonate, cesium carbonate, CsF, sodium pivalate, or the like; in an organic solvent such as DMF, DMA, DMSO, acetonitrile, propionitrile, butyronitrile, or an alcoholic solvent such as amyl alcohol; with or without the addition of a Cu (I) salt selected from cuprous chloride, cuprous iodide, cuprous bromide, or cuprous acetate; and optionally in the presence of a ligand such as 2-acetylcyclohexanone, TMEDA, or phenanthroline; and optionally in the presence of a reducing agent such as sodium ascorbate or sodium bisulfite; at a temperature in the range of from about room temperature to about 140 °C; to yield the corresponding compound of formula (2c- 2) wherein W is C1-8alkoxy or methylamino.
In one embodiment, the copper salt is cuprous bromide and the ligand is TMEDA.
In another embodiment, the Cu(0) source is copper powder.
In another embodiment, the Cu(0) source is copper sponge.
In a further embodiment, the organic solvent is DMA.
In a further embodiment, the organic solvent is DMSO.
In another embodiment, the reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a copper salt such as cuprous bromide with the ligand TMEDA; in the presence of the inorganic base potassium acetate; in an organic solvent such as DMA; at a temperature range of from about 80 °C to about 140 °C.
In another embodiment, the reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a Cu(0) source such as copper powder or copper sponge; in the presence of an inorganic base such as potassium acetate or sodium pivaiate; in DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
In another embodiment, the reaction of compound (XIII) with a compound of formula (2c- 1) comprises, consists of, and/or consists essentially of, a Cu (0) source such as copper powder or copper sponge; in the presence of an inorganic base such as potassium acetate; with the addition of a copper (I) salt selected from cuprous chloride, cuprous iodide, cuprous bromide, or cuprous acetate; in an organic solvent such as DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
The present invention further includes processes for the conversion of a compound of formula (2c-2) to compound (X), described in detail as follows.
Compound (XVII), wherein W is methylamino, may be reacted with a thiocarboiiyl source selected from Ο,Ο '-di(pyridin-2-yl)carbonothioate, l,r-thiocarbonylbis(pyridin- 2(lH)-one), di( lH-imidazol-l -yl)methanethione, thiophosgene, an aryl thionochloroformate (wherein aryl is phenyl, naphthyl, or tolyl), or thiocarbonyl bis(benzotriazole); in the presence of an activating agent selected from DMAP, NaH, or NaOH; in an organic solvent selected from DMA, DMF, toluene, DMSO, ACN, THF, DCM, EtOAc, acetone, MEK, or dioxane; optionally in the presence of an organic base selected from triethylamme or DIPEA; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound (X).
In one embodiment, the thiocarbonyl source is l, -thiocarbonylbis(pyridin-2(lH)- one).
In another embodiment, the activating agent is DMAP,
In another embodiment, the organic solvent is DMA.
In a further embodiment, the thiocarbonyl source is phenyl thionochloroformate; the activating agent is DMAP; the organic base is selected from triethylamine or DIPEA; the organic solvent is DMA; and at a temperature in the range of from about -20 °C to about 80 °C.
In another embodiment, phenyl thionochloroformate may react with DMAP to form an isoiatable quaternary salt, compound (SI), shown below.
Figure imgf000012_0001
The present invention is further directed to a process comprising, consists of, or consists essentially of reacting compound (XVII) with compound SI; in the presence of an organic base selected from triethylamine or DIPEA; in the organic solvent DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
A compound of formula (2c~2B), wherein W is Ci..gaikoxy, may be reacted with a thiocarbonyl source selected from Ο,Ο '-di(pyridin-2-yl)carbonothioate, 1 , I '
l l thiocarbonylbis(pyridin-2(lH)-one), di(lH-imidazol-l-yl)methanethione, thiophosgene, an aryl thionochloroformate (wherein aryl is phenyl, naphthyl, or tolyl), or thiocarbonyi bis(benzotriazole); in the presence of an activating agent selected from DMAP, NaH, or NaOH; in an organic solvent selected from dimethylacetamide, DMF, toluene, DMSO, THF, or dioxane; optionally in the presence of an organic base selected from triethylamine or DIPEA; at a temperature in the range of from about -20 °C to about 100 °C; to yield the to yield the corresponding compound (X).
In one embodiment, W of a compound of formula (2c-2B) is methoxy, designated as compound (XV).
The present invention is further directed to a process including reacting compound (2c- 2B) with compound SI; in the presence of an organic base selected from triethylamine or DIPEA; in the organic solvent DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
The compound of formula (2e) may be treated with methylamine; in an organic solvent selected from THF, DMF, DMA, ethanol, or an aqueous mixture thereof; at about ambient temperature; to yield the corresponding compound (X).
In one embodiment, the organic solvent is ethanol.
In another embodiment, the reaction conditions selected from Fl to Fl I, shown in Table 1 , may be used for the conversion of Cpd (2c-2) to either compound (X) or a compound of formula (2e), wherein W is methylamino or C1-8alkoxy, respectively.
Table 1.
Figure imgf000013_0001
Cpd (X) or a Cpd of formula (2e)
Figure imgf000014_0001
y met anet one 100
In another embodiment, when the thiocarbonyl source is phenyl
thionochloroformate, immediately after cvclization, DMAPA may be added.
Specific Examples
The following Examples are set forth to aid in the understanding of the invention, and are not intended and should not be construed to limit in any way the invention set forth in the claims that follow thereafter. In the Examples that follow, some synthesis products are listed as having been isolated as a residue. It will be understood by one of ordinary skill in the art that the term "residue" does not limit the physical state in which the product was isolated and may include, for example, a solid, an oil, a foam, a gum, a syrup, and the like.
Example 1
Figure imgf000015_0001
Preparation of Compound II.
Figure imgf000015_0002
II
A vessel was charged with 19 g of compound (I), 5 g of triethylamine
liydrobroniide, 49 g of xylenes and 67 g DMF. A solution of 26 g of phosphorous oxybromide in 16 g of xylene was dosed into the reaction mixture. The reaction mixture was heated to 100 °C for 3 h. The mixture was then cooled to 70 °C. To this mixture was added 75 g of a solution of NaOH (10M). After phase separation at room temperature, the organic layer was washed with a 84 g of an aqueous solution of NaOH (10M) followed by 84 g of an aqueous solution of NaCl (25 %). The organic phase was carried forward into the next step without further purification. Isolation by crystallization from heptane was performed for characterization purposes of compound (II). ¾ NMR (300 MHz, CDCI3) δ
Step B. Preparation of Compound III.
Figure imgf000016_0001
Ill
To the previous solution of compound (II) in xylenes was added 8.7 g of sodium cyanide and 6.8 g of copper (I) iodide and 45 g of butyronitrile. The mixture was heated to 120 °C for 20 h. The reaction mixture was cooled, washed twice with an aqueous solution of sodium carbonate (10%). The organic phase was carried forward into the next step. Isolation was performed for characterization purposes of compound (III). lH NMR (300 MHz, l)MS()-t/,.} δ 149.3, 145.4, 133.9, 131.9, 130.1 , 1 19.5, 114.0.
Figure imgf000016_0002
Preparation of modified catalyst slurry.
In a 20 mL beaker glass 0.156 g (0.129 raL, 50 % w/w) of H3PO2 was added to a slurry of 1.00 g 5 % Pt/C catalyst F101 R/W (from Evonik AG, contains -60 % water) and 4.0 mL of deionized water. After 15 minutes while stirrmg with a magnetic stirring bar, 58 rng of NH4VO3 was added and the slurry was again stirred for 15 minutes.
Hydrogenation.
A 100 mL autoclave was charged with a solution of 10.0 g of compound (III) (46.1 mmol) in 26.7 mL of xylenes and 13.3 mL of butyronitrile. To this solution, the modified catalyst slurry was added with the aid of 2 mL of deiomzed water. The autoclave was closed, then inertized by pressurizing 3 times with nitrogen to 10 bar and 3 times hydrogen to 10 bar. The reactor pressure was set to 5.0 bar hydrogen, stirring was started (hollow shaft turbine stirrer, 1200 rpm) and the mixture heated up to 70 °C within 50 mm. As soon as 70 °C was reached, the hydrogen uptake ceased. After stirring for another 40 mm, the heating was stopped and the autoclave was allowed to cooling. The slurry was filtered through a fiberglass filter and washed in portions using 40 mL of xylenes at 20-23 °C. Compound (IV) was crystallized from the solution upon distillation of the butvronitrile solvent. 1H NMR (300 Hz. DMSO-cfc) δ 8,20 (d, J=2,4Hz, H i). 7.31 (d, J=2.6Hz, i l l). 7.04 (s, Ni l ).
Preparation of Compound (XII).
Figure imgf000017_0001
Method A. To a mixture of 18 g (96.2 mmol) of compound (IV), 24.8 g (109.7 mmol) of compound (XI) in 54 mL of tetrahydrofuran (THF) was added 18.5 ml. (106 mmol) of N.N-diisopropylethylamine (DIPEA) and 17 g (104 mmol) of
carbonyldiimidazole (CDI) in portions at 20 °C. The mixture was heated to 60 °C and 15.4 g (101 mmol) l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was added. After 2 h, the mixture was diluted with 08 mL of tetrahydrofuran (THF) and washed with an aqueous solution of citric acid (50 g in 72 mL water). Subsequently, the water was partitioned away from the organic layer by means of an azeotropic distillation. Compound (XII) in
THF was used as such in the next step. A small sample was isolated for characterization purposes. Ή- NMR (300 MHz, CDC13) δ 10.4 (s, 1 H), 8.74 (s, 2H), 5.18 (s, 1 H), 2.79 (m, 2H), 2.22 (m, 2H), 2.12 (m, 2H), 1.49 (s, 9H); 13C NMR (CfX'k JMOD) δ 172.7, 143.6, 138.2, 131.0, 123.5, 123.3, 114.4, 82.2, 59.9, 30.7, 28.3, 15.1.
Method B. To a mixture of 40 g (214 mmol) of compound IV, 37.8 g (233 mmol) of carbonyldiimidazole (CDI, 109.7 mmol) in 120 mL of tetrahydrofuran ! f'i IF) was added a solution of 55 g (244 mmol) of compound (XI) in 240 mL of tetrahydrofuran (THF). The mixture was heated to 60 °C and 33.7 mL (224 mmol) l,8-diazabicyclo[5.4.0]undec- 7-ene (DBU) was added. After 4 h, the mixture was washed with an aqueous solution of citric acid (1 12 g in 160 mL of water). After phase separation at 50 °C, the water was separated from the organic layer by means of an azeotropic distillation. Compound (XII) in THF was used as such for the next step.
Step E. Preparation of Compound (XII) via 5-isocyanato-3-(trifluoromethy])
picolinonitrile, (IVa)
Figure imgf000018_0001
A reactor was charged with 0.2 g (1.1 mmol) of compound (IV), 6 mL of dry DCM, and cooled to 0 °C. Triphosgene (0.22 g, 0.67 eq) was added, followed by dropwise addition of triethylamine (0.55 g, 5 eq). The mixture was stirred at 0 °C, and after 2 h, compound (IV) was completely converted into compound (IVa) according to HPLC analysis. Compound (XI) (0.28 g, 1.2 eq) was added and the mixture was stirred further at 0 °C. HPLC analysis after 1 h showed 42% conversion to compound (XII) in the mixture.
Step F. Preparation of Compo nd (XIII).
Figure imgf000018_0002
A 6 M solution of hydrochloric acid in isopropanol (2 eq.) was added to solution of compound (XII) in THF. The stirred reaction solution was heated to 70 °C for 5 h. After reaction completion, the mixture is further heated to reflux and switched with 2-propanoi. The reaction was allowed to cool to 30 °C and a solution of ammonium hydroxide (3 eq.) was added. The mixture was stirred for 1 h then cooled to 5 °C. A precipitate was collected by filtration. The filter cake was washed once with water and once with cold isopropanol. The filter cake was dried under partial vacuum, at 50 °C to form, compound (XIII) in 80 % yield. Ή NMR (300 MHz, CDC13) δ 10.2 (s, 1H), 8.84 (s, 2H), 2.81 (m, 2H), 2.13 (m, 2H), 2.07 (m, 2H); 13C NMR (CDC13, JMOD) δ 175.8, 143.4, 137.5, 122.9, 1 4.4, 59,3, 34.9, 14.3, Step G. Preparation of Compound (XV)
Figure imgf000019_0001
Method A. A solution of 2 g of compound (XIII) in 10 mL of DMA was added over 6 h to a reactor charged with 1.2 eq of compound (XTv)-Cl (X=C1), 2,5 eq of potassium acetate, 1.0 eq of copper (I) chloride and 5 mL of DMA. The reaction mixture was stirred and heated to 130 °C. After 17 h additional stirring, HPLC analysis showed 40% of compound (XV) in the reaction mixture.
Method B. A reactor was charged with 1 g of compound (XIII), 1.18 g of compound (XTV)-I (X= I), 0.7 g of potassium acetate, 0.22 g of copper sponge (1 eq) and 7 mL of DMSO. The mixture was stirred at 25 °C for 7 h, HPLC analysis showed 93% conversion to compound (XV). After addition of EtOH, followed by water and
concentrated ammonium hydroxide, compound (XV) was isolated by filtration in 90% yield. 1H NMR (300 MHz, CDC13) δ 10.74 (m, 1 1 1). 9.28 (mJH), 8,75 (m, i l l). 7,67 (t, j 2 x 8.7 Hz, 1H), 7.55 (s, I I I ). 7.20 (in, 2H), 6.33 (d, i 8.51 ίκ. IH), 6.18 (d, J=13.8Hz, 1H), 3.75 (s, 3H) 2.76 (m, 2H), 2.24 (m, 2H), 1.98 (m, 2H); f 3C NMR (CDCI3, JMOD) δ 174.6, 164.4, 163.8, 161.1 , 151.7, 151.6, 144.7, 139.0, 133.1, 128.8, 128.1 , 123.8, 1 14.7, 109.10, 105.6, 60.6, 51.4, 30.1, 14.40.
Step H. Preparation of Compound (IX)
Figure imgf000020_0001
Method A. A reactor was charged with 1 g of compound (XV), 1.1 g of Ι,Γ- thiocarbonylbis(pyridin-2(lH)-one), 0.56 g of DMAP and 6.2 mL of DMA. The mixture was stirred and heated to 60 C'C for 20 h. At that time, 6 mL of EtOH was added, followed by 6 mL of water. The reaction was then cooled to 0 °C. Compound (IX) was isolated by filtration in 70 % yield. 1H NMR (300 MHz, DMSO) δ 9.23 ( s, j 1.9Hz. 1H), 8.77 ( s, j 2. I I I/. 1H), 8.18 ( t, J= 2x8,2Hz, 1H), 7.58 (dd, J= 10.9, 1.7 Hz, 1H), 7.48 (dd, J= 8.3, 1.7 Hz, 1H), 3.9 (s, 3H), 2.65 (m, 2H), 2.50 (m, 2H), 2.00 (m, 1H), 1.61 (m, 1H); i3C NMR (DMSO, JMOD) δ 179.6, 174.2, 163.3, 153.4 (ArH), 140.9, 135.5 (Aril), 132.9 (Aril), 128.9, 126.5 (ArH), 1 18.9 (ArH), 1 14.2, 67.7, 52,6 (CH3), 31.2, 13.4,
Method B. A reactor was charged with 0.5 g of compound (XV), 0,35 g (2.5 eq) of
DMAP and 5 mL. of DMA. The mixture was stirred and cooled to -20 °C. To this mixture, phenyl thionochloroformate (0.5 g, 2.5 eq) was added, followed by 0,46 g (4 eq) of triethvlamine. The mixture was allowed to warm to room temperature and stirred for 3 h. HPLC analysis showed 97 % conversion to compound (IX).
Step I Preparation of Compound (X) via Compound (IX).
Figure imgf000020_0002
A reactor was charged with 0.85 g of Compound (IX). A solution of methylamine in ethanol (8.5 mL) was added and the mixture was stirred at ambient temperature for 3 h. The reaction mixture was then poured into a mixture of 5.1 mL of acetic acid and 19 mL of water. Compound (X) was isolated by filtration in 55% yield. ¾H NMR (300 MHz, DM SO) δ 9.22 (s, IH), 8.79 (d, J=1.9Hz, IH), 8.52 (m, 1H), 7.83 (t, j 8x2Hz, 1H), 7.48 (dd, J 10.5, 1.8 Hz, I I I ). 7.39 (dd, J 8.2, 1.8 Hz, I I I ). 2.8 (d, J 4.5! !/. 3H), 2.65 (m, 2H), 2.50 (m, 2H), 2.00 (m, 1 1 1 ). 1.61 (m, IH).
Example 2
Figure imgf000021_0001
Step A. Preparation of Compound
Figure imgf000021_0002
Method A. To a 1 L reactor was charged with 7.8 g (38 mmol) compound (XVI)- Br (X=Br), 69.7 g (2.5 eq., 79 mmol) of potassium acetate, 12 g (0.3eq., 9.5 mmol) of copper (I) bromide and 12.8 mL (0.3 eq., 9.5 mmol) ϊΝ' ,Ν,Ν',Ν'- tetraniethylethylenediamine and 27 mL of DMA. The mixture was stirred and heated to 120 °C. A solution of 9.0 g of compound (XIII) in 12.7 mL of DMA was dosed over 2 h on the hot mixture. After 2 h additional stirring, the mixture was cooled to 60 °C. An addition of 27 mL of water followed by 18 mL of acetonitrile was completed. After seeding and aging 1 h, 8 mL of water was dosed slowly over 2 h. The mixture was cooled and then compound (XVfl) was isolated by filtration in 84% yield. 1H NMR (300 MHz, DMSO) δ 10.7 (s, 1H), 9.3 (s, 1H), 8.74 (s, 1H), 7.73 (m, i l l ). 7.47 (m, 1H), 7.19 (s, I I I ). 6.30 (d, J 8.31 1/.. 1H), 6.10 (d, ./ 13.9Hz, ! ! ! }. 2,70 (m, 3H), 2,70 (m), 2, 17 (m), 1.95 (m); 13C NMR (DMSO, JMOD) δ 175.0, 163,7, 162.3, 159.1, 149,6, 149.4, 144.6 (ArH), 139.0, 131 ,5 (ArH), 129,4, 129.0, 123.6 (ArH), 122.4, 120.0, 1 14,7, 11 1.4, 1 1 1.2, 109.2 (ArH), 99,5 (ArH), 60,6, 30.1 , 26.2, 14,3.
Method B. A reactor was charged 500 nig of compound (XIII), 1. 1 equivalents of compound (XVI)-Br (X=Br), 1 equivalent of copper powder, 2.0 equivalents of potassium acetate and 2.5 ml. of DMSO. The mixture was stirred and heated to 60 °C for 18 h, after which the HPLC showed that 80% of compound XVII was formed.
Step B. Preparation of Compound (X) from Compound (XVII).
Method A. A reactor was charged with 48 g of Compound ( XYH ), 52.8 g of 1, 1'- thiocarbonylbis(pyridin-2(lH)-one), 13.5 g of 4-dimethylaminopyridine and 144 mL of DMA. The mixture was stirred and heat to 90 °C for 2 h. The reaction was then cooled to 60 °C. A volume of 37 mL of HCl (6 M in isopropanoi) was added, followed by 144 mL of isopropanol and 216 raL of water. Compound (X) was isolated by filtration in 80 % yield.
Method B.
Figure imgf000022_0001
A portion of DMAP (hi 2, 2.0 g) was dissolved in 20 mL DCM and cooled to -30 °C. Phenyl thionochloroformate (Ml, 4.3 g, 1.5 eq) was added and the mixture stirred for 1 h. The mixture was filtered and the collected solid was dried at room temperature under reduced pressure to give 4.3 g of quaternary salt (SI) as a crystalline yellow product. Ί ί NMR (400 MHz, CD3CN): 3.39 (6H, s), 7.04 (2i l. d), 7.29 (211, d), 7.44 ( H i. t), 7.58 (2H, t), 9.04 (2H, d).
Compound (XVII) (0.5 g, 1.1 mmol) and triethylamine (0.93 g, 8.8 mmol) were dissolved in 5 mL DMA at 21 °C. Salt SI (0.81 g, 2.75 mmol) was added and the solution stirred at room temperature. Analysis of the solution by HPLC after 1 h showed 38% conversion to Compound (X).
Method C. DMAP (4.41 g, 2,2 eq, 36.1 mmol) was dissolved in 107 mL of ethyl acetate and heated to 60 °C. Compound (XVII) (7, 1 5 g, 16.4 mmol) was added followed by distillation of 35 mL of ethyl acetate to remove water. At 50 °C, 6.24 g (2.2 eq., 36.1 mmol) of phenyl thionochloroformate was added and the mixture was stirred for 1 h before addition of 9.16 mL (65.7 mmol) of triethylamine. The reaction was kept at 50 °C for 6 h, then cooled to 5 °C. 13.7 mL (5 eq., 82.1 mmol) of 6 M hydrochloric acid in 2-propanol was added. The mixture was then washed with 35.8 mL of water, followed by a brine wash. The resulting organic layer was evaporated and replaced with toluene and n- butanol. After seeding, the mixture was cooled and compound (X) was collected by filtration, washed and dried. Yield: 72 %.
Method D. DMAP (15.4 g, 2.2 eq) was dissolved in 250 mL of ethyl acetate.
Compound (XVII) (25 g) was added followed by heating to 50 °C. Phenyl
thionochloroformate (2.2 eq.) was added and the mixture was stirred for I h before the addition of 32 ml, (4.0 eq) of triethylamine. The reaction temperature was maintained at 50 °C for 6 h, then cooled to 20 °C. N^V-dimethy!propane- 1,3 -diamine (DMAP A) (2 eq.) was added and the mixture was stirred for 5 h. 6 M hydrochloric acid in 2-propanol (125 mL) was added and stirred for 2 h at 30 °C. The organic layer was then washed with 125 mL of water. The resulting organic layer was concentrated and replaced with H-butanol. After seeding, the mixture was cooled and compound (X) was collected by filtration, washed, and dried. Yield: 79 %.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

Claims

Vhat is claimed is:
A process for the preparation of compound (X)
Figure imgf000025_0001
comprising
Figure imgf000025_0002
reacting a compound of formula (XI-c), wherein P is an ammo protecting group, with compound (IV) under amide-bond formation conditions; in the presence of an amide coupling reagent; and in the presence of a catalyst; in an organic solvent; at a temperature in the range of from about 0 °C to about 50 °C; to yield the corresponding compound of formula (XII-c); or,
Figure imgf000025_0003
5-isocyanato-3-(trifluoromethyl)picolinonitrile (2a- 1) reacting compound (IV) with phosgene or a phosgene analog; in the presence of an organic base; in an aprotic solvent; then treating a resulting isocyanate intermediate (IVa), optionally without isolation, with a compound of formula (XI-c); in the presence of a non-nucleophilic base; at a temperature in the range of from about -20 °C to about 80 °C: to yield the corresponding compound of formula (Xii-c);
Figure imgf000026_0001
reacting a compound of formula (XII-c) under ammo deprotection conditions; in an organic solvent; at a temperature greater than ambient
temperature; to yield the corresponding compound (XIII);
Figure imgf000026_0002
reacting compound (XIII) with a compound of formula (2c- 1) wherein X is chloro, bromo, or iodo, and W is Ci-galkoxy or methylamino; in the presence of a copper (0) source or a copper salt; in the presence of an inorganic base; in an organic solvent; optionally in the presence of a ligand; optionally in the presence of a reducing agent; at a temperature in the range of from about room temperature to about 140 °C; to yield the corresponding compound of formula (2c-2) wherein W is Cj-saikoxy (2c-2B) or methylamino (XVII);
Figure imgf000026_0003
converting a compound of formula (2c-2) to compound (X).
2. The process of claim 1 wherein step (2a) further comprises
Figure imgf000027_0001
reacting a compound of formula (XI-c), wherein P is an amino protecting group, with compound (TV) under amide-bond formation conditions; in the presence of an amide coupling reagent selected from the group consisting of 1,1 - carbonyldiimidazole, T3P, EDCI, DMTMM, and EEDQ; in the presence of a catalyst selected from the group consisting of DBU, DBN, DABCO, triethylarnine, DIPEA, TBD, TMG, MTBD, NaH, KOtBu, and LiHMDS; in an organic solvent selected from the group consisting of toluene, MeTHF, THF, iPrOAc, DCM, and IPA; at a temperature in the range of from about 0 °C to about 50 °C; to yield the corresponding compound of formula (ΧΠ-c).
The process of claim 2 wherein the amide coupling agent is 1,1 - carbonyldi imidazole and the catalyst is DBU.
The process of claim 1 wherein step (2a- i } further comprises
Figure imgf000027_0002
5-isocyanato-3-(trifluoromethyl)picolinonitrile (¾- J ) reacting compound (IV) with phosgene or a phosgene analog selected from the group consisting of triphosgene (bis(trichloromethyl) carbonate) and diphosgene (trichloromethyl chloroformate); in the presence of an organic base selected from the group consisting of triethylarnine, ethyl diisopropylamine, and DABCO; in an aprotic solvent that is DCM, toluene, THF, or MeTHF; at a temperature in the range of from about -20 °C to about 50 °C; to form an
isocyanate intermediate (IVa); then reacting said isocyanate intermediate (IVa) with a compound of formula (ΧΓ-c); in the presence of a non-nucleophilic base selected from the group consisting of DBU, DBN, DABCO, triethylamine, TBD, TMG, and MTBD; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound of formula (XII-c).
The process of claim 1 wherein step (2c) further comprises
Figure imgf000028_0001
reacting compound (XIII) with a compound of formula (2c- 1) wherein X is chloro, bromo, or iodo, and W is Cj .salkoxy or methylamino; in the presence of either (I) a copper (0) source that is copper powder or copper sponge, or (2) a copper salt selected from the group consisting of cuprous chloride, cuprous iodide, cuprous bromide, cuprous acetate, and cupric bromide; in the presence of an inorganic base selected from the group consisting of pota ssium acetate, pota ssium carbonate, cesium carbonate, and CsF; in an organic solvent that is DMF, DMA, DMSO, acetonitrile, propionitrile, butyronitrile, or amyl alcohol; with or without the addition of a copper (I) salt selected from the group consisting of cuprous chloride, cuprous iodide, cuprous bromide, and cuprous acetate; and, optionally in the presence of a ligand selected from the group consisting of 2- acetylcyclohexanone, TMEDA, and phenanthroline; also, optionally in the presence of a reducing agent that is sodium ascorbate or sodium bisulfite; at a temperature in the range of from about room temperature to about 140 °C; to yield the
corresponding compound of formula (2c-2) wherein W is C j.galkoxy (2c-2B) or methylamino (XVII).
6. The process of claim 5, comprising reacting compound (XIII) with a compound of formula (2c- 1) in the presence of cuprous bromide; in the presence of TMEDA; in the presence of potassium acetate; in organic solvent DMA; at a temperature in the range of from about 80 °C to about 140 °C.
7. The process of claim 5, comprising reacting compound (XIII) with a compound of formula (2c- 1) in the presence of a copper (0) source that is copper powder or copper sponge; in the presence of potassium acetate or sodium pivalate; in organic solvent DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
8. The process of claim 5, comprising reacting compound (XIII) with a compound of formula (2c- 1) in the presence of a copper (0) source that is copper powder or copper sponge; in the presence of potassium acetate; with the addition of a copper (I) salt selected from the group consisting of cuprous chloride, cuprous iodide, cuprous bromide, and cuprous acetate; in organic solvent DMSO; at a temperature in the range of from about 0 °C to about 80 °C.
9. The process of claim 1, wherein step (2d) further comprises the conversion of compound (Χ ΤΙ) to compound (X) by
Figure imgf000029_0001
reacting compound (XVII) with a thiocarbonyl source; in the presence of an activating agent; in an organic solvent; optionally in the presence of an organic base; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound (X).
10. The process of claim 9, wherein step (2e) further comprises reacting compound (XVII) with a thiocarbonyl source selected from the group consisting of Ο,Ο '- di(pyridin-2-yl)carbonothioate, 1 , 1 '-thiocarbonylbis(pyridin-2(lH)-one), di(lH- imidazoi-l-yl)methanethione, thiophosgene, phenyl thionochloroformate, 0~{2- naphthyl) thionochloroformate, tolyl thionochloroformate, and thiocarbonyl bis(benzotriazole): in the presence of an activating agent selected from the group consisting of DMAP, NaH, and NaOH; in an organic solvent selected from the group consisting of DMA, DMF, toluene, DMSO, ACN, THF, DCM, EtOAc, acetone, MEK, and dioxane; optionally in the presence of an organic base selected from triethylamine or DIPEA; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound (X).
1 1. The process of claim 10 wherein the thiocarbonyl source is 1 , 1 '- thiocarbonylbis(pyridin-2(lH)-one).
12. The process of claim 1 1 wherein the activating agent is DMAP.
13. The process of claim 12 wherein the organic solvent is DMA.
14. The process of claim 10 wherein the thiocarbonyl source is phenyl
thionochloroformate; the activating agent is DMAP; the organic base is triethylamine or DIPEA; the organic solvent is DMA; at a temperature in the range of from about -20 °C to about 80 °C.
15. The process of claim 10 wherein the thiocarbonyl source is phenyl
thionochloroformate; the activating agent is DMAP; the organic base is triethylamine or DIPEA; the organic solvent is acetone or ethyl acetate; at a temperature in the range of from about -20 °C to about 80 °C. The process of claim 15 wherein immediately after cyclization, DMAPA is added.
The process of claim 10, wherein step (2e) further comprises reacting phenyl thionocliloroformate with DMAP to form an isolatable quaternaiy salt, compound (SI),
Figure imgf000031_0001
S1
then, reacting compound (XVII) with compound SI; in the presence of an organic base selected from triethyiamine or DIPEA; in DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
18. The process of claim 1 , wherein step (2d) further comprises the conversion of a compound of formula (2c-2B) to a compound of formula (2e), by
Figure imgf000031_0002
reacting a compound of formula (2c~2B) with a thiocarbonyl source; in the presence of an activating agent; in an organic solvent; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound of formula (2e); then,
Figure imgf000031_0003
treating a compound of formula (2e) with methylamine; i an organic solvent; at about ambient temperature; to yield the corresponding compound (X).
19. The process of claim 18, further comprising reacting a compound of formula (2c- 2B) with a thiocarbonyl source selected from the group consisting of Ο,Ο '- di(pyridin-2-yl)carbonothioate, l, -thiocarbonylbis(pyridin-2(lH)-one), di(lH- imidazol-l-yl)methanethione, thiophosgene, phenyl thionochloroformate, 0-(2- naphthyi) thionochloroformate, tolyl thionochloroformate, and thiocarbonyl bis(benzotriazole); in the presence of an activating agent selected from the group consisting of DMAP, NaH, and NaOH; in an organic solvent selected from the group consisting of dimethylacetamide, DMF, toluene, DMSO, THF, and dioxane; at a temperature in the range of from about -20 °C to about 100 °C; to yield the corresponding compound of formula (2e); then
treating the compound of formula (2e) with methylamine; in an organic solvent selected from the group consisting of THF, DMF, DMA, ethanol, and an aqueous mixture thereof; at about ambient temperature; to yield the corresponding compound (X),
20. The process of claim 19 wherein treating the compound of formula (2e) with
methylamine further comprises using ethanol as the organic solvent.
21. The process of claim 19 further comprising reacting a compound of formula (2c- 2B) wherein the thiocarbonyl source is phenyl thionochloroformate; the activating agent is DMAP; the organic solvent is acetone or ethyl acetate; at a temperature in the range of from about -20 °C to 40 °C; to yield the corresponding compound of formula (2e); then
treating the compound of formula (2e) with methylamine; in ethanol; at about room temperature; to yield the corresponding compound (X). The process of claim 18, wherein step (2f) further comprises reacting phenyl thionochloroformate with DMAP to form an isolatable quaternary salt, compound
(SI),
Figure imgf000033_0001
S1 ; then,
reacting compound (2c-2B) with compound SI; in the presence of an organic base selected from triethylamine or DIPEA; in DMA; at a temperature in the range of from about -20 °C to about 80 °C; to yield the corresponding compound (X).
23. A process for the preparation of com ound (II)
Figure imgf000033_0002
II
comprising
mixing compound (I) in the presence of triethylamine hydrobromide; in the presence of DMF; in xylenes as a solvent;
adding a solution of phosphorous oxybromide in xylenes to compound (I); heating to about 100 °C for about 3 h; then,
cooling the reaction mixture to about 70 °C before adding NaOH to obtain compound (II).
24. A process for the preparation f compound
Figure imgf000033_0003
III
comprising reacting a solution of compound (II) in xylenes with sodium cyanide; in the presence of copper (I) iodide; in butyronitrile; at a temperature of about 120 °C; to obtain compound (III).
A process for the preparation of com ound (IV)
Figure imgf000034_0001
IV
comprising
preparing a catalyst slurry by adding H3P02 to a slurry of 5 % Pt/C catalyst
F101 R/W and deionized water while stirring;
adding NH4VO3 to the slurry while stirring for about 15 min; then reacting compound (III) with said cataiyst slurry; in an organic solvent or mixture of solvents selected from the group consisting of xylenes and butyronitrile; under an inert atmosphere; in the presence of hydrogen gas; at a temperature of about 70 °C; to obtain compound (IV).
A compound of formula (XII-c), useful for the preparation of compound (X), wherein P is an amino protecting group
Figure imgf000034_0002
27. The compound of claim 26 wherein P is t-butoxycarbonyl.
28. A compound ( Xf f f )
Figure imgf000035_0001
useful for the preparation of compound (X).
19. A compound (XVII)
Figure imgf000035_0002
useful for the preparation of compound (X).
A compound of formula (2c-2B)
Figure imgf000035_0003
useful for the preparation of compound (X).
PCT/US2015/066356 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound WO2016100652A2 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
DK15823875.8T DK3233803T3 (en) 2014-12-19 2015-12-17 PROCEDURE FOR THE PREPARATION OF A DIARYLTHIO-HYDANTO COMPOUND
JP2017532725A JP6681902B2 (en) 2014-12-19 2015-12-17 Process for preparing diarylthiohydantoin compounds
EP18170050.1A EP3372586A1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
EP18169895.2A EP3372585B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
KR1020177019551A KR102586059B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
PL18169756T PL3372584T3 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
MDE20170208T MD3233803T2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
ES15823875T ES2718539T3 (en) 2014-12-19 2015-12-17 Process for the preparation of a compound of diaryltiohyddanine
AU2015364537A AU2015364537B2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
IL252843A IL252843B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
MEP-2019-86A ME03420B (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
EP15823875.8A EP3233803B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
MX2017008179A MX2017008179A (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound.
PL15823875T PL3233803T3 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
UAA201707588A UA123201C2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
CA2970937A CA2970937A1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
BR112017013113-7A BR112017013113B1 (en) 2014-12-19 2015-12-17 PROCESS FOR PREPARING A DIARYLTHIHOHYDANTOIN COMPOUND
EP18169756.6A EP3372584B9 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
EA201791390A EA201791390A1 (en) 2014-12-19 2015-12-17 METHOD FOR PREPARING DIARYLTIOHYDANTOINE COMPOUND
NZ732766A NZ732766A (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
MA41200A MA41200B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
SI201530599T SI3233803T1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
CN201580069602.5A CN107108507B (en) 2014-12-19 2015-12-17 Process for preparing diaryl thiohydantoin compounds
SG11201704969QA SG11201704969QA (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
RS20190350A RS58454B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
CN202410667649.2A CN118638097A (en) 2014-12-19 2015-12-17 Preparation of diaryl thiohydantoin Process for the preparation of ureide compounds
LTEP15823875.8T LT3233803T (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
PH12017501152A PH12017501152A1 (en) 2014-12-19 2017-06-19 Process for the preparation of a diarylthiohydantoin compound
ZA2017/04877A ZA201704877B (en) 2014-12-19 2017-07-18 Process for the preparation of a diarylthiohydantoin compound
HRP20190540TT HRP20190540T1 (en) 2014-12-19 2019-03-19 Process for the preparation of a diarylthiohydantoin compound
CY20191100400T CY1121684T1 (en) 2014-12-19 2019-04-10 METHOD FOR THE PREPARATION OF A DIARYLTHIOYADANTOINE COMPOUND
CY20201101031T CY1123611T1 (en) 2014-12-19 2020-11-02 METHOD FOR THE PREPARATION OF A DIARYLTHIOYADANTOINE COMPOUND

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19
US62/094,436 2014-12-19

Publications (2)

Publication Number Publication Date
WO2016100652A2 true WO2016100652A2 (en) 2016-06-23
WO2016100652A3 WO2016100652A3 (en) 2016-08-25

Family

ID=55168400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/066356 WO2016100652A2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Country Status (33)

Country Link
US (1) US9688655B2 (en)
EP (4) EP3372586A1 (en)
JP (2) JP6681902B2 (en)
KR (1) KR102586059B1 (en)
CN (2) CN107108507B (en)
AR (1) AR103228A1 (en)
AU (1) AU2015364537B2 (en)
BR (1) BR112017013113B1 (en)
CA (1) CA2970937A1 (en)
CY (2) CY1121684T1 (en)
DK (3) DK3233803T3 (en)
EA (4) EA201892486A1 (en)
ES (3) ES2827549T3 (en)
HR (3) HRP20220750T1 (en)
HU (2) HUE042409T2 (en)
IL (1) IL252843B1 (en)
LT (3) LT3372584T (en)
MA (1) MA41200B1 (en)
MD (1) MD3233803T2 (en)
ME (1) ME03420B (en)
MX (1) MX2017008179A (en)
NZ (1) NZ732766A (en)
PH (1) PH12017501152A1 (en)
PL (3) PL3233803T3 (en)
PT (3) PT3233803T (en)
RS (3) RS63455B1 (en)
SG (4) SG10201912802XA (en)
SI (3) SI3372584T1 (en)
TR (1) TR201904739T4 (en)
TW (4) TWI683810B (en)
UA (1) UA123201C2 (en)
WO (1) WO2016100652A2 (en)
ZA (1) ZA201704877B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501237A (en) * 2017-08-17 2017-12-22 上海西浦医药科技有限公司 A kind of Apalutamide new synthetic method
CN108069869A (en) * 2016-11-09 2018-05-25 上海医药工业研究院 A kind of Preparation Method And Their Intermediate of Apalutamide
WO2018136001A1 (en) * 2017-01-18 2018-07-26 Scinopharm Taiwan, Ltd. Process for preparing apalutamide
WO2018224423A1 (en) 2017-06-07 2018-12-13 Chiesi Farmaceutici S.P.A. (4-(([1,2,4]triazolo[4,3-a]pyridine-6-yl)oxy)-1,2,3,4-tetrahydronaphthalen-1-yl) ureido derivatives as anti-inflammatory p38 mapk inhibitors for treating diseases of the respiratory tract
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017008178A (en) 2014-12-19 2018-03-06 Aragon Pharmaceuticals Inc Processes for the preparation of a diarylthiohydantoin compound.
PL3233803T3 (en) * 2014-12-19 2019-07-31 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound
CN108383749B (en) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 Synthetic method of apaluamide and intermediate thereof
CN108314646B (en) * 2018-04-11 2021-03-19 武汉慧敏科技中心 Method for preparing drug intermediate for urogenital system from high-dispersion bimetal nano material
CN109651256A (en) * 2018-11-20 2019-04-19 上海健康医学院 A kind of preparation method of the miscellaneous Shandong amine of the grace of formula (VIII)
CN110511207A (en) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 Aryl -2- thiohydantoin class compound intermediate, preparation method and application
CN110511206A (en) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 Aryl -2- thiohydantoin class compound intermediate, preparation method and application
CN113968815A (en) * 2020-07-24 2022-01-25 苏州科伦药物研究有限公司 Synthetic method of thiodiazaspiro compound, intermediate and synthetic method thereof
CN113402466B (en) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 Apaglucone intermediate and method for preparing apalone
CN113292535B (en) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 Method for preparing apaluamide intermediate and apaluamide
CN115850233A (en) * 2021-09-24 2023-03-28 南京方生和医药科技有限公司 Synthetic method of apalutamide
CN115536634B (en) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 Synthesis method of apatamide
CN116332907A (en) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 Preparation method of amorphous apatamide
CN117645572A (en) * 2023-11-23 2024-03-05 奥锐特药业股份有限公司 Preparation method of enzae Lu An and intermediate thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445507B2 (en) 2006-03-27 2013-05-21 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2294053B1 (en) 2008-05-16 2016-01-06 Takeda California, Inc. Glucokinase activators
BR112012015868A2 (en) 2009-12-11 2017-06-20 Autifony Therapeutics Ltd imidazolidinedione derivatives
EA028869B1 (en) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Androgen receptor modulators and use thereof
MX2012009782A (en) * 2010-02-24 2012-11-29 Medivation Prostate Therapeutics Inc Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds.
DK2683694T3 (en) 2011-03-10 2016-07-18 Suzhou Kintor Pharmaceuticals Inc ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013148375A1 (en) * 2012-03-29 2013-10-03 Sangart, Inc. Diaspirin crosslinked pegylated hemoglobin
WO2014190895A1 (en) * 2013-05-29 2014-12-04 成都海创药业有限公司 Imidazole diketone compound and use thereof
PL3233803T3 (en) * 2014-12-19 2019-07-31 Aragon Pharmaceuticals, Inc. Process for the preparation of a diarylthiohydantoin compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445507B2 (en) 2006-03-27 2013-05-21 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108069869A (en) * 2016-11-09 2018-05-25 上海医药工业研究院 A kind of Preparation Method And Their Intermediate of Apalutamide
WO2018136001A1 (en) * 2017-01-18 2018-07-26 Scinopharm Taiwan, Ltd. Process for preparing apalutamide
WO2018224423A1 (en) 2017-06-07 2018-12-13 Chiesi Farmaceutici S.P.A. (4-(([1,2,4]triazolo[4,3-a]pyridine-6-yl)oxy)-1,2,3,4-tetrahydronaphthalen-1-yl) ureido derivatives as anti-inflammatory p38 mapk inhibitors for treating diseases of the respiratory tract
CN107501237A (en) * 2017-08-17 2017-12-22 上海西浦医药科技有限公司 A kind of Apalutamide new synthetic method
CN107501237B (en) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 Synthetic method of Apalutamide
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide

Also Published As

Publication number Publication date
DK3372584T5 (en) 2021-05-17
DK3233803T3 (en) 2019-04-08
PT3372584T (en) 2020-11-13
JP6903785B2 (en) 2021-07-14
US9688655B2 (en) 2017-06-27
PT3233803T (en) 2019-05-20
PL3372585T3 (en) 2022-10-10
EP3372584B9 (en) 2021-03-31
ME03420B (en) 2020-01-20
PL3233803T3 (en) 2019-07-31
US20160176845A1 (en) 2016-06-23
SI3372584T1 (en) 2021-08-31
SG10201912802XA (en) 2020-02-27
JP2018501237A (en) 2018-01-18
CN118638097A (en) 2024-09-13
EA201892485A1 (en) 2019-07-31
SI3372585T1 (en) 2022-08-31
LT3372585T (en) 2022-07-11
CN107108507B (en) 2024-05-28
EA201892487A1 (en) 2019-07-31
HRP20220750T1 (en) 2022-09-02
RS63455B1 (en) 2022-08-31
MD3233803T2 (en) 2019-07-31
ZA201704877B (en) 2019-02-27
RS61060B9 (en) 2021-07-30
HRP20190540T1 (en) 2019-06-14
EP3372586A1 (en) 2018-09-12
EP3372585A1 (en) 2018-09-12
TW201639825A (en) 2016-11-16
EP3372584B1 (en) 2020-09-23
CY1123611T1 (en) 2022-03-24
DK3372585T3 (en) 2022-05-30
PT3372585T (en) 2022-07-08
EA201791390A1 (en) 2017-10-31
UA123201C2 (en) 2021-03-03
MA41200B1 (en) 2019-05-31
HUE042409T2 (en) 2019-06-28
EP3233803B1 (en) 2019-01-30
ES2827549T3 (en) 2021-05-21
ES2718539T3 (en) 2019-07-02
TW202031639A (en) 2020-09-01
TWI683810B (en) 2020-02-01
TWI703132B (en) 2020-09-01
ES2827549T9 (en) 2021-07-02
SG10201912811QA (en) 2020-02-27
BR112017013113A2 (en) 2017-12-26
EA201892486A1 (en) 2019-07-31
DK3372584T3 (en) 2021-01-04
AR103228A1 (en) 2017-04-26
KR102586059B1 (en) 2023-10-05
HUE052475T2 (en) 2021-05-28
RS61060B1 (en) 2020-12-31
RS58454B1 (en) 2019-04-30
IL252843A0 (en) 2017-08-31
AU2015364537A1 (en) 2017-07-06
WO2016100652A3 (en) 2016-08-25
CN107108507A (en) 2017-08-29
MX2017008179A (en) 2017-09-18
ES2919951T3 (en) 2022-07-29
EP3372584A1 (en) 2018-09-12
HRP20201847T1 (en) 2021-03-19
TWI689494B (en) 2020-04-01
EP3372585B1 (en) 2022-03-30
HRP20201847T2 (en) 2021-05-28
MA41200A (en) 2017-10-25
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (en) 2021-07-05
KR20170095976A (en) 2017-08-23
LT3233803T (en) 2019-04-10
TW201945343A (en) 2019-12-01
CA2970937A1 (en) 2016-06-23
IL252843B1 (en) 2024-10-01
SG11201704969QA (en) 2017-07-28
SG10201912805SA (en) 2020-02-27
TR201904739T4 (en) 2019-05-21
JP6681902B2 (en) 2020-04-15
BR112017013113B1 (en) 2023-11-21
EP3233803A2 (en) 2017-10-25
TWI753336B (en) 2022-01-21
NZ732766A (en) 2023-07-28
CY1121684T1 (en) 2020-07-31
TW201945342A (en) 2019-12-01
SI3233803T1 (en) 2019-05-31
LT3372584T (en) 2020-12-10
JP2020114842A (en) 2020-07-30
AU2015364537B2 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
AU2015364537B2 (en) Process for the preparation of a diarylthiohydantoin compound
DK3233823T3 (en) PROCEDURES FOR THE PREPARATION OF A DIARYLTHIO HYDANTOIN COMPOUND
TW201609696A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
CA2966800A1 (en) Synthesis of copanlisib and its dihydrochloride salt
EP3421456A1 (en) New route of synthesis for opicapone
US20160176844A1 (en) Processes for the preparation of a diarylthiohydantoin compound
TWI617562B (en) An improved process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine from 4-amino-2,5-dimethoxypyrimidine
EA041899B1 (en) METHOD FOR PRODUCING DIARYLTHOHYDANTOIN COMPOUND

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15823875

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 252843

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2970937

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017532725

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201704969Q

Country of ref document: SG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201580069602.5

Country of ref document: CN

Ref document number: MX/A/2017/008179

Country of ref document: MX

Ref document number: 12017501152

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2015823875

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017013113

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015364537

Country of ref document: AU

Date of ref document: 20151217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177019551

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201707588

Country of ref document: UA

Ref document number: 201791390

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112017013113

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170619